Walled Lake Planning & Wealth Management LLC Has $1.09 Million Position in Pfizer Inc. (NYSE:PFE)

Walled Lake Planning & Wealth Management LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 68.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,987 shares of the biopharmaceutical company's stock after selling 88,666 shares during the period. Walled Lake Planning & Wealth Management LLC's holdings in Pfizer were worth $1,087,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its position in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI raised its stake in shares of Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. NFJ Investment Group LLC boosted its holdings in shares of Pfizer by 12.8% in the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after acquiring an additional 43,719 shares in the last quarter. Copley Financial Group Inc. bought a new stake in Pfizer during the 3rd quarter worth approximately $577,000. Finally, Zacks Investment Management increased its holdings in Pfizer by 10.9% during the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock valued at $69,142,000 after purchasing an additional 235,243 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Remove Ads

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Trading Up 0.3 %

Shares of NYSE:PFE traded up $0.08 during midday trading on Wednesday, hitting $24.62. The company had a trading volume of 18,608,774 shares, compared to its average volume of 39,126,591. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.33 and a 12 month high of $31.54. The firm has a fifty day simple moving average of $26.00 and a 200 day simple moving average of $26.84. The stock has a market cap of $139.63 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Bank of America restated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.